Defective apoptosis not only promotes tumorigenesis, but also can confound chemotherapeutic response. Here we demonstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a determinant in paclitaxel sensitivity in vivo. Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway conferred resistance to paclitaxel that was dependent on functional inactivation of BIM. Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes. The proteasome inhibitor Velcade (P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-dependent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.
Introduction
and perhaps also by directly activating the function of BAX and BAK (Adams, 2003b) . Either BAX or BAK is required for apoptosis, which is associated with their oligomerization in the Programmed cell death or apoptosis occurs in response to developmental cues and disease states, and serves to sculpt tissues, mitochondrial outer membrane and its permeablization to proapoptotic mitochondrial proteins such as cytochrome c and eradicate abnormal or infected cells, and maintain homeostasis. Acquired resistance toward apoptosis is considered to be a uni-SMAC/Diablo. Loss of both BAX and BAK therefore results in profound resistance to many apoptotic stimuli, including death versal feature of cancer Hanahan and Weinberg, 2000) . Defects in apoptosis not only provide cancer cells receptor signaling and genotoxic agents (Degenhardt et al., 2002a; Wei et al., 2001; Zong et al., 2001) . with an intrinsic survival advantage, but may also confer inherent resistance to chemotherapeutic drugs (Johnstone et al., The strong impact of the BCL-2 family on tumor development is well illustrated by findings with baby mouse kidney 2002). BCL-2 family proteins are central players in the regulation of apoptosis, and modulate death signaling through the epithelial (BMK) cells transformed by E1A and dominant negative p53 (p53DD). Transformed BMK cells from mice deficient intrinsic or mitochondrial pathway . Whereas BCL-2 and several close relatives promote cell surfor both BAX and BAK, or that overexpress BCL-2, readily form tumors in nude mice, whereas those retaining functional BAX vival, other family members that share several domains with BCL-2, such as BAX and BAK, instead favor apoptosis. Memand/or BAK do not (Degenhardt et al., 2002a; Nelson et al., 2004) . In epithelial cells, ischemic conditions in the tumor mibers of the more distantly related BH3-only subfamily (BIM, PUMA, NOXA, BID, BAD, and BIK, for example) have the criticroenvironment cause induction of the BH3-only protein PUMA, and BAX-and BAK-mediated apoptosis that suppresses tucal role of initiating the apoptotic program. They act by antagonizing the function of antiapoptotic BCL-2 and its homologs, morigenesis independent of the RB and p53 pathways (Nelson
S I G N I F I C A N C E
Tumorigenesis results in the acquisition of mutations that promote tumor growth and chemoresistance, and relating tumor genotype to prognostic indications and to effective treatment regimens is essential for successful therapeutic outcome. Determining the mechanism of apoptosis induction by the chemotherapeutic drug paclitaxel revealed that BIM suppressed tumorigenesis and was required for paclitaxel responsiveness. The targeting of BIM for degradation in proteasomes by the H-ras/MAPK pathway was the molecular basis for paclitaxel resistance in tumors with activating mutations in RAS, and paclitaxel responsiveness was restored by joint administration of the proteasome inhibitor Velcade. Thus, rational combinatorial chemotherapy using proteasome inhibitors to enhance chemosensitivity to paclitaxel in tumors where the H-ras/MAPK pathway is activated may be therapeutically beneficial. et al., 2004) . Blockade of this p53-independent apoptotic pathbilize microtubules, causing mitotic arrest and activating the spindle assembly checkpoint, the signal transduction pathway by either loss-of-function of BAX and BAK or gain-of-function of BCL-2 in vivo does not merely extend viability, but also ways by which paclitaxel induces apoptosis are still poorly understood (Bhalla, 2003) . allows survival of genetically unstable cells which may further promote tumor development (Nelson et al., 2004) . However,
We have developed and utilized isogenic transformed epithelial cells with defined combinations of gain-and loss-ofhow the RB, p53, and BCL-2 pathways impact chemotherapeutic response and functionally interact with other known function mutations to evaluate the impact on both tumor growth and treatment response. We report here that paclitaxel induces pathways, such as those of receptor tyrosine kinases, is still not clear.
BIM accumulation that is required for paclitaxel-induced apoptosis both in vitro and in vivo. However, constitutive activation The frequent activation of RAS signaling pathways during tumorigenesis is also likely to reflect in part their ability to inhibit of the H-ras/MAPK pathway suppresses BIM induction by phosphorylating BIM and targeting BIM for degradation in proapoptosis (Downward, 2003) . Downstream of RAS, AKT/PKB signaling has been shown to desensitize cells to apoptosis by teasomes, thereby blocking response to paclitaxel. Nevertheless, in cells with the RAS pathway activated, combined treatphosphorylating various targets, whereas the mechanisms by which the RAF/MAPK pathway blocks apoptosis are less well ment with a proteasome inhibitor and paclitaxel restores BIM accumulation and apoptosis. Finally, we show that BIM is indefined. In the MAPK pathway, a survival signal is transduced from RAS through serine/threonine kinase RAF, which in turn deed a tumor suppressor in epithelial cells, and that BIM deficiency results in paclitaxel-resistant tumors. This provides a phosphorylates and activates MAPK kinases MEK1/2 and thereby the p42/44 MAPK (ERK1/2) (Downward, 2003) . The mechanistic explanation for chemotherapeutic-mediated apoptosis and suggests that combining a proteasome inhibitor MEK/ERK cascade can inhibit apoptosis by upregulating the antiapoptotic proteins BCL-2, BCL-X L , and MCL-1 (Jost et al.,
with paclitaxel would provide therapeutic benefit among tumors with H-ras/MAPK pathway activation. 2001; Leu et al., 2000; Liu et al., 1999) . It may also promote survival both by phosphorylating BCL-2 and blocking its degradation in proteasomes (Dimmeler et al., 1999) and by phosResults phorylating BIM and accelerating its proteasomal degradation (Akiyama et al., 2003; Ley et al., 2003; Luciano et al., 2003) .
Expression of H-ras confers resistance to paclitaxel
Since mutations that activate a ras gene are among the most In this study, we have investigated the role of BIM and its regulation by the RAS/RAF/MAPK pathway in control of apocommon found in tumors, we sought to determine how constitutive RAS activity alters the apoptotic response during cheptosis during both tumorigenesis and chemotherapeutic response. There are two major BIM isoforms: the longer BIM-EL motherapy. Hence, we have investigated how imposed H-ras expression affects the paclitaxel sensitivity of transformed predominating over BIM-L, and a shorter form (BIM-S) which is sometimes detectable (O'Connor et al., 1998) . A central role BMK epithelial cells with genetically defined defects in apoptosis. Transformed BMK cells that express BAX and BAK (W2 for BIM-mediated apoptosis in maintenance of hematopoietic homeostasis was indicated by the aberrant accumulation of cells) (Degenhardt et al., 2002a) were transfected with plasmids directing constitutive expression of H-ras or BCL-2, or with the lymphoid and myeloid cells in BIM-deficient mice (Bouillet et al., 1999; Bouillet et al., 2002) . BIM functions through proteinvector. Isogenic BAX-and BAK-deficient transformed BMK cells (D3 cells) (Degenhardt et al., 2002a) were also transfected protein interactions, and its proapoptotic activity can be inhibited by association with BCL-2, BCL-X L , BCL-w, and MCL-1 with plasmids directing constitutive expression of H-ras or with the vector to test if H-ras enhanced the survival in the back- (Opferman et al., 2003; Wilson-Annan et al., 2003; Yamaguchi and Wang, 2002; Zhu et al., 2004) . Genetic evidence for the ground of BAX/BAK deficiency. Three independent clones of each genotype that stably express H-ras (data not shown) were mutually antagonistic roles of BIM and BCL-2 came with the demonstration that the apoptosis of kidney cells, melanocytes, treated with paclitaxel and viability was determined. The viability of one representative clone of each genotype is shown in and lymphocytes provoked by BCL-2 deficiency was precluded by concomitant deficiency for BIM (Bouillet et al., 2001) . Figure 1A . Importantly, the vector control cell line derived from W2 cells Finally, BIM also interacts with microtubule-associated dynein complex by binding to dynein light chain 1 (DLC1) LC8, which (W2.3.1-5) was readily killed by paclitaxel, and this cell death was blocked by the expression of H-ras (W2.Hras-3). Expression of may relate BIM function to regulation of the cytoskeleton (Puthalakath et al., 1999) .
antiapoptotic BCL-2 (W2.Bcl2-3) or deficiency of proapoptotic BAX and BAK (D3.zeo-2) (Nelson et al., 2004) conferred slightly BIM has been reported to be a tumor suppressor for mature B lymphocytes in Eµ-myc-transgenic mice, and is haploinsuffimore resistance to apoptosis than H-ras (W2.Hras-3) ( Figure 1A ). cient (Egle et al., 2004) . However, due to the multiplicity of Furthermore, the expression of H-ras in BAX/BAK-deficient cells BH3-only proteins, and the complexity of their expression and (D3.Hras-1) did not further enhance survival ( Figure 1A ), suggestregulation, it is not possible to predict whether BIM could serve ing that H-ras inhibited paclitaxel-mediated apoptosis by blockthat role in other cell types, such as the epithelial cells that ing the BAX/BAK apoptotic pathway. produce all the common solid tumors. Interestingly, in vitro studies (Bouillet et al., 1999; Sunters et al., 2003) have also Paclitaxel induces BIM accumulation that is blocked by H-ras implicated BIM in the apoptosis induced by paclitaxel, an anticancer agent that interferes with microtubule dynamics. PacliAs BH3-only proteins are essential triggers of apoptosis upstream of BAX and BAK (Adams, 2003b; Cheng et al., 2001 ), taxel is a frontline antineoplastic agent that is efficacious in the treatment of a number of malignancies, including ovarian, H-ras might act by affecting the function of BH3-only proteins that mediate paclitaxel-induced apoptosis. The resistance of breast, lung, and prostate cancers. Although it is known to sta- A: Viability of transformed BMK cells in response to paclitaxel. W2.3.1-5, W2.Bcl2-3, W2.Hras-3, D3.Hras-1, and D3.zeo-2 were treated with 300 nM paclitaxel for four days. The viable cell number was counted before (day 0) and each day after treatment by trypan blue exclusion. Results are presented as relative survival with error bars representing standard deviation. B: Paclitaxel induces BIM accumulation, which is blocked by H-ras. W2.3.1-5, W2.Hras-3, D3.zeo-2, and D3.Hras-1 were untreated or treated with 300 nM paclitaxel for four days, and the expression of BH3-only proteins BIM, BID, tBID, PUMA, and BMF was analyzed by Western blotting. Actin is shown as a control for protein loading. C: H-ras causes BIM-EL and BIM-L phosphorylation. D3.zeo-2 and D3.Hras-1 whole cell lysates were incubated with lambda protein phosphatase, resolved by SDS-PAGE, and Western blotted for BIM to establish that the slower migrating forms of BIM are the result of phosphorylation.
BIM-deficient lymphocytes in vitro to paclitaxel (Bouillet et al., BIM-EL and BIM-L were present as multiple distinctively migrating bands, the slowest of which were preferentially ob-1999) led us to investigate the role of BIM in H-ras-dependent paclitaxel resistance in epithelial cells. Western blotting reserved in H-ras-expressing cells ( Figure 1B) , and BIM-EL is a substrate for phosphorylation by the RAF/MAPK pathways vealed that the levels of BIM-L and particularly the more predominant BIM-EL isoform were upregulated dramatically in downstream of H-ras (Marani et al., 2004) . In contrast, W2.3.1-5 and D3.zeo-2 cells predominantly displayed the faster migrat-W2.3.1-5 and D3.zeo-2 cells following paclitaxel treatment ( Figure 1B) . As D3.zeo-2 cells did not undergo apoptosis in ing BIM-EL and BIM-L, suggesting that they were unphosphorylated. To confirm that the slower migrating forms of BIM-EL response to paclitaxel ( Figure 1A ), BIM induction was not a consequence of cell death. Notably, BIM induction by pacliand BIM-L resulted from phosphorylation by H-ras, lysates of D3.zeo-2 and D3.Hras-1 cells were incubated with lambda protaxel was largely abrogated by the H-ras expression in both W2.Hras-3 and D3.Hras-1 cells ( Figure 1B) . Thus, H-ras regutein phosphatase. As expected, phosphatase treatment converted both BIM-EL and BIM-L to monomeric forms with enlates both BIM accumulation and apoptosis by paclitaxel. Because the levels of other BH3-only proteins, namely BID, tBID, hanced mobility ( Figure 1C ). Thus, H-ras expression caused BIM phosphorylation and specifically prevented BIM induction PUMA, and BMF, were unchanged by paclitaxel treatment (Figby paclitaxel, suggesting that H-ras may confer resistance to ure 1B), BIM appears to have a specific role in paclitaxelthe drug by modulating BIM levels. induced cell death. BIM induction is not merely a general response to cellular damage, because another cytotoxic drug, the topoisomerase II inhibitor etoposide, did not induce BIM The MAPK pathway regulates BIM and blocks the apoptotic response to paclitaxel accumulation (see Supplemental Figure S1 ). Interestingly, BID was only cleaved to tBID in W2.3.1-5 cells that underwent apoTo define the downstream effector pathway through which H-ras interferes with paclitaxel-induced apoptosis, W2 cells ptosis in response to paclitaxel, and not in apoptosis-resistant D3 cells, suggesting that BID cleavage resulted from caspase were transfected with the vector, or vectors that express constitutively activated forms of RAF (RAF-CAAX) or AKT (Myractivation ( Figure 1B ).
To test if phosphorylation of BIM by H-ras was also a function of H-ras signaling through RAF/MAPK pathway, the cell lines were treated with paclitaxel, and BIM protein levels were measured by Western blotting. As expected, BIM isoforms were phosphorylated in H-ras-or RAF-CAAX-expressing cells, neither of which accumulated BIM in response to paclitaxel ( Figure 2B ). In contrast, BIM was unphosphorylated and highly induced in response to paclitaxel in both W2 vector control cells and W2 cells expressing Myr-AKT ( Figure 2B ). Hence, H-ras may suppress paclitaxel-induced apoptosis through MAPK pathway by phosphorylating BIM and blocking BIM accumulation. To confirm that the MEK/ERK pathway downstream of H-ras is responsible for phosphorylation of BIM by H-ras, the specific MEK1/2 inhibitor U0126 was used to block MEK1/2 activity, which as expected prevented BIM phosphorylation in H-ras expressing cells (see Supplemental Figure S2 ).
H-ras provides resistance to paclitaxel by preventing BIM accumulation
To determine if paclitaxel-induced apoptosis was mediated by BIM, multiple independent E1A and p53DD transformed BMK cell lines that were deficient for BIM (bim ( Figure 1A ), presumably because of their extreme defect in nM paclitaxel for three days, and cell extracts were subjected to Western apoptosis. Thus, a gain-of-function of H-ras or RAF in the blotting for BIM. Actin is shown as a loading control.
background of BIM deficiency should have been apparent. The absence of a gain-of-function of H-ras or RAF in BIM-deficient cells indicates that they block paclitaxel-induced apoptosis by inhibiting BIM. AKT). Three independent cell lines of each genotype were treated with paclitaxel, and viability was determined. BMK cells BIM, but not PUMA, suppresses tumorigenesis expressing RAF-CAAX were resistant to paclitaxel to a similar Since tumorigenesis and chemoresistance often concur in extent as cells expressing H-ras (Figure 2A ). In contrast, cells apoptotic defective cells, we investigated the impact of BIM expressing Myr-AKT were as sensitive to paclitaxel as vector deficiency on tumorigenesis, by comparing tumor developcontrol cell lines (Figure 2A ). These data suggest that H-ras ment with three independent BIM-deficient (BIM
−/−
A, B, and C) provides resistance to paclitaxel in BMK cells through RAF/ MAPK pathway.
and BIM wild-type (BIM
+/+
A, B, and C) transformed BMK cell C) were subjected to Western blotting with antibodies specific for BIM, E1A, p53, BAK, BAX, and actin. B: BIM deficiency confers resistance to paclitaxel. Three independent BMK cell lines that express BIM or that are deficient for BIM were treated with 100 nM paclitaxel for three days, and viability was evaluated as described above. Results are presented as relative survival with error bars representing standard deviation. A, B, and C) were also tested. Cells from all the lines were injected subcutaneously though unlike the E-myc B cell lymphomas (Egle et al., 2004), we did not observe haploinsufficiency. As BAX and BAK are into nude mice, and tumor growth was monitored.
As previously reported (Degenhardt et al., 2002a ; Nelson et absolutely required for apoptosis, their deficiency may be more effective at blocking apoptosis than the loss-of-function of one al., 2004), the BAX/BAK-deficient control (D3) formed large tumors (carcinomas) within 30 days, whereas a transformed cell of the upstream BH3-only proteins such as BIM.
To address the possibility that BH3-only protein deficiency line expressing BAX and BAK (W2) formed no measurable tumors ( Figure 4A ). Significantly, two of the three BIM-deficient may shift the balance toward the antiapoptotic state and that deletion of any BH3-only protein would nonspecifically protransformed BMK cell lines formed tumors at a rate comparable to that of the BAX/BAK deficient D3 cells, and the third cell mote tumorigenesis, we tested the tumorigenic potential of E1A plus p53DD-transformed puma −/− BMK cells ( Figure 4B ) line also eventually formed tumors ( Figure 4A ). In contrast, all three BMK cell lines heterozygous for BIM and two of the three derived from PUMA-deficient mice (Villunger et al., 2003) . The observation that PUMA-deficient transformed BMK cells were BMK cell lines wild-type for BIM were as nontumorigenic as Complete response is defined as the complete disappearance of the RFP signal, partial response is defined as progressive loss of RFP signal beyond three weeks following treatment, but still detectable, and no response is defined as no detectable loss of RFP signal. The number of mice showing a response in each category is shown over the total number of mice in each group, and the percent responding is shown in parenthesis. A were engineered contrast to BIM deficiency, PUMA deficiency was not sufficient to promote tumorigenesis of epithelial cells ( Figure 4B ). In addito express red fluorescent protein (RFP), and the mice were monitored by whole-animal optical imaging. Figure 4D shows tion, PUMA-deficient cells were sensitive to paclitaxel, but displayed resistance to thapsigargin, an inducer of ER-stressrepresentative mice from each treatment group (vehicle or paclitaxel) prior to and after paclitaxel administration. BIM +/+ A mediated apoptosis ( Figure 4C ), consistent with a previous study (Reimertz et al., 2003) . Thus, although BIM and PUMA cells persisted in the vehicle control-treated animals and eventually formed tumors of 0.5 cm in diameter by eight are both proapoptotic BH3-only BCL-2 antagonists, their functions are apparently pathway-specific.
weeks, whereas the RFP signal progressively regressed and completely disappeared after paclitaxel treatment, and no tumors formed during the total 14 weeks of monitoring. In con-BIM confers paclitaxel sensitivity in vivo We investigated the role of BIM in the apoptotic response to trast, BIM
−/−
A cells persisted in both the paclitaxel and vehicle control groups for over three weeks, and tumors formed within paclitaxel in vivo, by testing the ability of the drug to prevent 
H-ras/MAPK signaling promotes BIM degradation in proteasomes
It has been reported recently that phosphorylation of BIM by the ERK1/2 pathway accelerates BIM-EL degradation in proteasomes (Ley et al., 2004; Luciano et al., 2003) . Therefore, we explored whether RAS prevented BIM induction by paclitaxel by inducing its phosphorylation and turnover. To obviate any contribution of cell death to BIM turnover, the effect of H-ras on BIM stability was assessed in the BAX/BAK-deficient D3 cells. D3.zeo-2 and D3.Hras-1 cells were incubated with or without paclitaxel for 24 hr, the protein synthesis inhibitor cycloheximide (CHX) was added, and the subsequent decay in BIM levels was monitored by Western blotting. In the absence of paclitaxel, BIM-EL levels fell slowly in D3.zeo-2 cells, with a half-life in excess of four hours, but H-ras expression accelerated BIM turnover to a half-life of less than two hours (Figure 5A ). Though paclitaxel enhanced BIM stability in the D3. zeo-2 cells, BIM turnover was greatly accelerated in the D3. Hras-1 cells ( Figure 5A ). Thus, paclitaxel enhances BIM stability, but H-ras expression facilitates BIM turnover even in the presence of paclitaxel.
To determine if the degradation of BIM-EL proceeded via a duces BIM accumulation, and BIM function is required for apoptosis induction by paclitaxel, this suggests that H-ras expression suppresses BIM accumulation by targeting BIM for degradation in proteasomes, thereby blocking apoptosis. H-ras expression were comparable ( Figure 5D ). After 48 hr of Since BIM protein levels reportedly can be regulated at the paclitaxel treatment, the mRNA level increased modestly in transcription level through the MAPK, AKT/Forkhead, or JNK both D3.zeo-2 cells and D3.Hras-1 cells, suggesting that uppathways in certain cell types (Marani et al., 2004; Putcha et regulation of BIM mRNA by paclitaxel may contribute to accual., 2003), we tested whether RAS also blocks BIM induction mulation of the protein independently of H-ras. We conclude that the predominant mechanism by which H-ras prevents BIM in response to paclitaxel at the mRNA level. The basal BIM mRNA levels in BMK cells with (D3.Hras-1) or without (D3.zeo-2) induction by paclitaxel is stimulation of BIM turnover. , demonstrating that the synergy between Velcade and alone, the combined treatment was highly cytotoxic, even paclitaxel requires BIM. Thus, proteasome inhibition abrogated when H-ras was expressed ( Figure 6A ). In striking contrast, the paclitaxel resistance in vivo imposed by H-ras, by rescuing BIM-deficient cells expressing H-ras were markedly resistant BIM responsiveness to paclitaxel. to the combination of paclitaxel and epoxomycin ( Figure 6A ). The small epoxomycin and paclitaxel synergy observable at 24 Discussion hr in BIM-deficient cells might indicate the existence of proteaMany anticancer agents induce apoptosis, and chemoresissome targets other than BIM. Restoration of paclitaxel sensitivtance can occur when tumors are unable to efficiently engage ity by epoxomicin in BIM +/+ A.Hras-B cells correlated with resapoptotic programs. Since apoptotic defects are selected for toration of BIM accumulation ( Figure 6B ). This is not a specific during tumorigenesis, the process of tumor evolution may also effect of epoxomicin, because the proteasome inhibitor Velselect for drug resistance. Indeed, BIM has proven to be a tucade, which is currently in clinical trials as an anticancer agent mor suppressor both in epithelial solid tumors ( Figure 4A ) and and has been approved by the FDA for use in multiple mylymphomas (Egle et al., 2004) , and also is a major determinant eloma, also restored BIM induction by paclitaxel and abrogated in paclitaxel sensitivity ( Figures 4D-4F) . Similarly, H-ras and the H-ras-dependent resistance in BIM wild-type but not BIM-defi-MAPK pathway are commonly mutated in human tumors, and cient cells (Figures 6C and 6D) . Thus, H-ras inhibits paclitaxelwe show that RAS/MAPK activation suppresses BIM accumumediated apoptosis by phosphorylating BIM via the MAPK lation and thereby ablates the proapoptotic response to paclipathway and promoting its degradation in proteasomes.
taxel. Thus, common mutational events that arise during tumor formation can directly or indirectly disable the apoptotic maProteasome inhibition abrogates H-ras-dependent paclitaxel resistance in vivo chinery and confound cancer treatment. Just as BCL-2 is an oncoprotein, evidence is emerging that The ability of proteasome inhibitors to abrogate the paclitaxel resistance conveyed by H-ras encouraged us to test whether several of the BH3-only proteins may suppress the development of very specific types of tumors. Mice lacking BID have proteasome inhibition could sensitize H-ras-expressing cells to paclitaxel in vivo. The efficacy of cotreatment with Velcade an increased tendency to develop chronic myelomonocytic A.Hras-C cells were injected subcutaneously into nude mice. When the tumors reached 0.5 cm in diameter (day 0), the mice were assigned randomly into each of the following groups with 5-9 mice/ group: control, Velcade, paclitaxel, or Velcade and paclitaxel. Each mouse received 0.55 mg/ kg Velcade and/or 10 mg/kg paclitaxel intraperitoneally on days 1, 3, 5, 7 as arrows indicate. Mannitol dissolved in normal saline was used as vehicle for Velcade; 52.7 mg/ml cremophor and 5% (v/v) ethanol dissolved in normal saline was used as vehicle for paclitaxel. Day 0 represents the day before treatment. Each point represents the average tumor volume of each group, with standard deviation. Note that Velcade sensitized H-ras-expressing BMK cells to paclitaxel in the presence of BIM (A) but failed to sensitize H-ras-expressing BMK cells to paclitaxel in the absence of BIM (B). C: A model for the mechanism by which H-ras modulates BIM and confers resistance to paclitaxel. See text for details.
leukemia (Zinkel et al., 2003) , and some aged BAD-deficient genesis. As PUMA deficiency alone was insufficient to promote epithelial tumorigenesis, PUMA function may only be manimice develop diffuse large cell lymphoma (Ranger et al., 2003) . Similarly, either PUMA knockdown or BIM deficiency promotes fested in the absence of BIM. Alternatively, PUMA may be a tumor suppressor in other situations, as it mediates both p53-the development of B cell lymphomas in E-myc transgenic mice (Egle et al., 2004; Hemann et al., 2004) . The contribution dependent and -independent apoptosis, and NOXA or other BH3-only proteins may function redundantly with PUMA. of BH3-only proteins to suppression of epithelial solid tumor formation, however, was unknown. We showed previously that BIM has been implicated in mediating paclitaxel-induced apoptosis in vitro (Bouillet et al., 1999; Sunters et al., 2003) , BAX-or BAK-dependent apoptosis suppresses tumorigenesis of transformed BMK cells independently from p53 function and we demonstrate here that there is an essential role of BIM in paclitaxel-induced apoptosis in vivo. Paclitaxel not only ef- (Degenhardt et al., 2002a) . As BH3-only proteins function upstream of BAX and BAK, identification of those BH3-only profectively inhibited epithelial tumor establishment, but also strikingly induced regression of established tumors. However, this teins, and the apoptotic pathways that they regulate to control apoptosis during solid tumor formation, is of great interest. chemotherapeutic effect required BIM, because it was completely abrogated by BIM deficiency. Moreover, H-ras expresHere we demonstrate that BIM, but not PUMA, deficiency promotes epithelial tumorigenesis ( Figures 4A and 4B) . The human sion conferred resistance to paclitaxel-induced apoptosis by promoting BIM degradation in proteasomes, and BIM inhibition Bim gene (official name BCL2L11) may well also be a tumor suppressor, because it is located in a region (chromosome promoted both epithelial tumor growth and drug resistance. Pertinently, combined chemotherapy with paclitaxel and the 2q13) where alterations, predominantly deletions, have been reported in human malignancies, more than half of the cases MER/ERK inhibitor U0126 was shown to enhance induction of cell death in human tumors (MacKeigan et al., 2000 ; McDaid being epithelial in origin (http://cgap.nci.nih.gov/Chromosomes/ Mitelman).
and Horwitz, 2001), but the underlying mechanism is not known. Since the BMK cells studied here had been transformed with genes that disrupt the RB and p53 pathways, BIM clearly conHere, we correlate RAS-dependent paclitaxel resistance and BIM regulation by the RAS/MAPK pathway ( Figure 7C ). In trols a checkpoint independent of those major routes to tumorigenesis. BIM deficiency was somewhat less efficient in tumor transformed BMK epithelial cells, paclitaxel caused upregulation of both BIM mRNA and protein, resulting in BIM accumulapromotion than combined deficiency in BAX and BAK. As BAX and BAK seem to be required for apoptosis mediated by all tion and apoptosis. Although BIM has been shown to be regulated transcriptionally by RAS or its downstream effectors in BH3-only proteins, whereas the latter are activated by specific stimuli , this result may well indicate different scenarios, basal levels of BIM mRNA and its upregulation by paclitaxel were not significantly affected by H-ras. Howthat another BH3-only protein can also contribute to epithelial tumorigenesis. Indeed, PUMA and not BIM is induced by ischever, activation of the RAS/MAPK pathway prevented BIM induction by paclitaxel by stimulating BIM phosphorylation and emic conditions in the tumor microenvironment in vivo during BAX-and BAK-mediated tumor regression (Nelson et al., degradation via the ubiquitin proteasome pathway, thereby producing resistance to paclitaxel ( Figure 7C ). As BCL-2 and 2004), and PUMA may synergize with BIM to suppress tumori-
Generation of stable cell lines

MCL-1 bind to and compromise BIM function, we tested
The generation of E1A plus p53DD transformed BMK cell lines were dewhether phosphorylation of BIM by H-ras would modulate its scribed previously (Degenhardt et al., 2002b (Lin et al., 1995) few other cytotoxic agents (Teicher et al., 1999) , but the underlying mechanism of the cooperative effect is not known.
Western blotting
A notorious oncogenic pathway activated by proteasome
The following antibodies were used: rabbit anti-BIM (Axxora, LLC, San degradation is the NF-κB pathway (Ravi and Bedi, 2004) . Pro- types, and it can also be induced by chemotherapy, radiation, (Cell Signaling Technology, Beverly, MA) . Cell extracts were generated in Laemmli buffer, and Western blotting was performed as previously deand other cellular stresses. Inhibition NF-κB activation has scribed (Nelson et al., 2004) .
been proposed as a mechanism of Velcade action (Adams, 2003a) , but NF-κB-independent activity of Velcade has also Phosphatase digestion of BIM been reported . Our results identify an alterna-D3.zeo-2 and D3.Hras-1 cells were harvested in 2% CHAPS lysis buffer tive pathway responsive to Velcade that may be both drug-and with protease inhibitors, as previously described (Cuconati et al., 2003) . Whole cell lysates were incubated with lambda protein phosphatase (NEB, tumor genotype-specific. Velcade sensitized BIM wild-type but Beverly, MA) at 30°C for two hours and then analyzed by Western blotting.
not BIM-deficient BMK cells expressing H-ras to paclitaxelinduced apoptosis both in vitro and in vivo, indicating that this
Real-time PCR
paclitaxel/Velcade synergy is BIM-dependent. Thus, combina-RT-PCR was carried out as previously described (Cuconati et al., 2003) . Gene-specific primer pairs and probe sequences for bim: forward (5#-TGC tion therapy with paclitaxel and proteasome inhibitors may be GCC CGG AGA TAC G-3#), reverse (5#-CCT CCT TGT GTA AGT TTC GTT particularly useful in treating paclitaxel-resistant tumors with GAA C-3#), and probe (5#-/56-FAM/CGA TCC GCC GCA GCT CCT GT/36-mutations activating MAPK signaling. Interestingly, combinaTAMTph/-3#). Primers and probe for mouse gapdh PCR were obtained from tion therapy with Velcade and the paclitaxel-related drug doApplied Biosystems, which served as an internal control and were used to cetaxel was not always effective against pancreatic cancer, normalize for variances in input cDNA.
which frequently harbors Ras mutations (Nawrocki et al., 2004) , suggesting that the regulation of chemotherapeutic responses
Supplemental data
by BIM and H-ras may be influenced by yet other factors.
Supplemental data for this article can be found at http://www.cancercell.
The armamentarium of potential anticancer drugs is expanding;
org/cgi/content/full/7/3/227/DC1/.
however, single agents may not suffice to achieve complete remission. Velcade is currently being evaluated in combination with
